AbbVie (ABBV) climbs after raising full-year earnings guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ROIV
2. HUVR:IN
3. NVS
4. TTE
5. ANET
6. NKE
7. BE
8. PANW
9. CL
10. SNDK

Go back to AbbVie (ABBV) climbs after raising full-year earnings guidance

AbbVie Reports Second-Quarter 2023 Financial Results

July 27, 2023 7:38 AM EDT

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational BasisSecond-Quarter Global Net Revenues from the Immunology Portfolio Were $6.813 Billion, a Decrease of 5.5 Percent on a Reported Basis,... More

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

July 26, 2023 9:00 AM EDT

NORTH CHICAGO, Ill. and LA JOLLA, Calif., July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps Research... More